SCHATZ, Bugie and Waksman1 introduced streptomycin in January 1944 and reported the definite suppressive action of this new agent, among others, on cultures of Mycobacterium tuberculosis. In the same year Feldman and Hinshaw noted the therapeutic effect of streptomycin in experimental tuberculosis and followed this in 1945 with a preliminary report on the use of this antibiotic in the treatment of clinical tuberculosis.2 Since that time the literature on streptomycin therapy has become voluminous. The indications for the use of streptomycin in pulmonary tuberculosis have become more or less uniformly standardized, and the favorable results of this treatment on tuberculosis of numerous extrapulmonary organs have been acknowledged.
However, while its beneficial action, particularly on lesions of the mucous membranes, has been observed, only very few reports of the therapeutic value of streptomycin or dihydrostreptomycin in oral tuberculosis have been published so far. This paucity of available data may justify the
OPPENHEIM H, LIVINGSTON CS, NIXON JW, MILLER CD. STREPTOMYCIN THERAPY IN ORAL TUBERCULOSIS. AMA Arch Otolaryngol. 1950;52(6):910–929. doi:10.1001/archotol.1950.00700030937008
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: